About Enanta Pharmaceuticals (NASDAQ:ENTA)
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ENTA
CUSIPN/A
Phone617-607-0800
Debt
Debt-to-Equity RatioN/A
Current Ratio12.88%
Quick Ratio12.88%
Price-To-Earnings
Trailing P/E Ratio46.53
Forward P/E Ratio84.07
P/E GrowthN/A
Sales & Book Value
Annual Sales$102.81 million
Price / Sales16.29
Cash Flow$1.0529 per share
Price / Cash83.04
Book Value$15.80 per share
Price / Book5.53
Profitability
EPS (Most Recent Fiscal Year)$0.91
Net Income$17.71 million
Net Margins26.35%
Return on Equity13.33%
Return on Assets12.50%
Miscellaneous
Employees89
Outstanding Shares19,160,000
Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions
What is Enanta Pharmaceuticals' stock symbol?
Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."
How were Enanta Pharmaceuticals' earnings last quarter?
Enanta Pharmaceuticals (NASDAQ:ENTA) posted its earnings results on Wednesday, February, 7th. The biotechnology company reported $0.78 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.05 by $0.73. The biotechnology company earned $38.11 million during the quarter, compared to the consensus estimate of $27.26 million. Enanta Pharmaceuticals had a net margin of 26.35% and a return on equity of 13.33%. View Enanta Pharmaceuticals' Earnings History.
When is Enanta Pharmaceuticals' next earnings date?
What price target have analysts set for ENTA?
4 equities research analysts have issued twelve-month price objectives for Enanta Pharmaceuticals' stock. Their predictions range from $36.00 to $80.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $51.75 in the next year. View Analyst Ratings for Enanta Pharmaceuticals.
Who are some of Enanta Pharmaceuticals' key competitors?
Some companies that are related to Enanta Pharmaceuticals include Array Biopharma (ARRY), Tesaro (TSRO), Clovis Oncology (CLVS), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Ironwood Pharmaceuticals (IRWD), Evotec A.G. (EVTCY), Puma Biotechnology (PBYI), Acadia Pharmaceuticals (ACAD), Supernus Pharmaceuticals (SUPN), Akorn (AKRX), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), The Medicines (MDCO), Portola Pharmaceuticals (PTLA) and Heron Therapeutics (HRTX).
Who are Enanta Pharmaceuticals' key executives?
Enanta Pharmaceuticals' management team includes the folowing people:
- Dr. Jay R. Luly, Pres, CEO & Director (Age 62)
- Mr. Paul J. Mellett Jr., Sr. VP-Fin. & Admin., CFO and Principal Accounting Officer (Age 63)
- Dr. Yat Sun Or, Sr. VP-R&D and Chief Scientific Officer (Age 66)
- Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 52)
- Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 64)
Has Enanta Pharmaceuticals been receiving favorable news coverage?
Headlines about ENTA stock have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Enanta Pharmaceuticals earned a coverage optimism score of 0.17 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 45.80 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Enanta Pharmaceuticals?
Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Enanta Pharmaceuticals' stock price today?
One share of ENTA stock can currently be purchased for approximately $87.43.
How big of a company is Enanta Pharmaceuticals?
Enanta Pharmaceuticals has a market capitalization of $1.71 billion and generates $102.81 million in revenue each year. The biotechnology company earns $17.71 million in net income (profit) each year or $0.91 on an earnings per share basis. Enanta Pharmaceuticals employs 89 workers across the globe.
How can I contact Enanta Pharmaceuticals?
Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]
MarketBeat Community Rating for Enanta Pharmaceuticals (ENTA)
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Enanta Pharmaceuticals in the last 12 months. Their average twelve-month price target is $51.75, suggesting that the stock has a possible downside of 40.81%. The high price target for ENTA is $80.00 and the low price target for ENTA is $36.00. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Buy | Buy |
| Consensus Rating Score: | 2.25 | 2.25 | 2.50 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $51.75 | $51.25 | $45.25 | $45.25 |
| Price Target Upside: | 40.81% downside | 42.45% downside | 22.89% downside | 6.04% downside |
Enanta Pharmaceuticals (NASDAQ:ENTA) Consensus Price Target History
Enanta Pharmaceuticals (NASDAQ:ENTA) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Enanta Pharmaceuticals (NASDAQ:ENTA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Enanta Pharmaceuticals (NASDAQ ENTA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.56%
Institutional Ownership Percentage: 73.26%
Enanta Pharmaceuticals (NASDAQ ENTA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/16/2018 | Nathalie Adda | VP | Sell | 4,225 | $85.58 | $361,575.50 | 10,225 |  |
| 3/19/2018 | Paul J Mellett | Treasurer | Sell | 9,000 | $86.48 | $778,320.00 | 96,458 | |
| 1/4/2017 | Yat Sun Or | Insider | Sell | 13,921 | $35.09 | $488,487.89 | 301,876 | |
| 11/29/2016 | Yat Sun Or | Insider | Sell | 13,921 | $31.44 | $437,676.24 | 315,797 | |
| 5/11/2016 | Nathaniel S Gardiner | VP | Buy | 500 | $24.45 | $12,225.00 | 1,900 | |
| 2/12/2016 | Terry Vance | Director | Buy | 2,000 | $27.04 | $54,080.00 | 15,295 | |
| 11/24/2015 | Paul J. Mellett | CFO | Sell | 6,000 | $30.15 | $180,900.00 | 54,397 | |
| 10/15/2015 | Paul J Mellett | CFO | Sell | 7,500 | $40.10 | $300,750.00 | 60,397 | |
| 9/8/2015 | Paul J. Mellett | CFO | Sell | 7,500 | $39.55 | $296,625.00 | 67,897 | |
| 7/13/2015 | Paul J Mellett | CFO | Sell | 7,500 | $46.29 | $347,175.00 | | |
| 7/13/2015 | Yat Sun Or | Insider | Sell | 3,750 | $46.29 | $173,587.50 | | |
| 6/11/2015 | Paul J Mellett | CFO | Sell | 7,500 | $42.51 | $318,825.00 | | |
| 6/11/2015 | Yat Sun Or | Insider | Sell | 3,750 | $42.47 | $159,262.50 | | |
| 6/5/2015 | Yat Sun Or | Insider | Sell | 10,750 | $42.02 | $451,715.00 | | |
| 5/19/2015 | Paul J Mellett | CFO | Sell | 24,000 | $40.13 | $963,120.00 | | |
| 5/11/2015 | Yat Sun Or | Insider | Sell | 8,000 | $36.13 | $289,040.00 | | |
| 3/9/2015 | Jay R Luly | CEO | Sell | 15,000 | $33.37 | $500,550.00 | | |
| 2/20/2015 | Jay R Luly | CEO | Sell | 15,000 | $35.35 | $530,250.00 | | |
| 2/19/2015 | Stephen Jr. Buckley | Director | Buy | 1,000 | $34.00 | $34,000.00 | | |
| 2/17/2015 | Nathaniel S Gardiner | VP | Buy | 1,400 | $33.23 | $46,522.00 | | |
| 1/16/2015 | Paul J Mellett | CFO | Sell | 4,500 | $49.45 | $222,525.00 | | |
| 1/5/2015 | Jay R Luly | CEO | Sell | 15,000 | $50.43 | $756,450.00 | | |
| 12/1/2014 | Jay R Luly | CEO | Sell | 15,000 | $45.39 | $680,850.00 | | |
| 11/3/2014 | Jay R Luly | CEO | Sell | 15,000 | $42.52 | $637,800.00 | | |
| 9/15/2014 | Paul J Mellett | CFO | Sell | 10,000 | $39.83 | $398,300.00 | | |
| 8/14/2014 | Paul J Mellett | CFO | Sell | 10,000 | $39.13 | $391,300.00 | | |
| 8/14/2014 | Stephen Jr. Buckley | Director | Buy | 1,000 | $38.95 | $38,950.00 | | |
| 7/14/2014 | Paul J Mellett | CFO | Sell | 20,000 | $39.88 | $797,600.00 | | |
| 5/1/2014 | Yat Sun Or | Insider | Sell | 5,000 | $36.98 | $184,900.00 | 184,078 | |
| 4/1/2014 | Jay Luly | CEO | Sell | 15,000 | $39.17 | $587,550.00 | 544,338 | |
| 4/1/2014 | Yat Sun Or | Insider | Sell | 10,000 | $39.16 | $391,600.00 | 189,078 | |
| 3/24/2014 | Yat Sun Or | Insider | Sell | 10,000 | $39.34 | $393,400.00 | 199,078 | |
| 3/4/2014 | V Life Science Ventures Gm Tvm | major shareholder | Sell | 439,334 | $38.82 | $17,054,945.88 | | |
| 2/26/2014 | V Life Science Ventures Gm Tvm | major shareholder | Sell | 230,190 | $39.15 | $9,011,938.50 | | |
| 2/24/2014 | V Life Science Ventures Gm Tvm | major shareholder | Sell | 60,477 | $39.57 | $2,393,074.89 | | |
| 2/14/2014 | Jay Luly | CEO | Sell | 5,800 | $38.10 | $220,980.00 | 569,338 | |
| 1/2/2014 | Jay R Luly | CEO | Sell | 5,800 | $28.05 | $162,690.00 | | |
| 12/6/2013 | Marc E Goldberg | Director | Sell | 6,861 | $27.93 | $191,627.73 | | |
| 10/14/2013 | Saints Capital Granite, L.P. | Major Shareholder | Sell | 32,301 | $19.84 | $640,851.84 | | |
| 10/10/2013 | Saints Capital Granite, L.P. | Major Shareholder | Sell | 36,207 | $21.71 | $786,053.97 | | |
| 10/3/2013 | Saints Capital Granite, L.P. | Major Shareholder | Sell | 12,300 | $23.39 | $287,697.00 | | |
| 3/26/2013 | Helmut Schuhsler | Director | Buy | 132,949 | $14.00 | $1,861,286.00 | | |
| 3/26/2013 | Saints Capital Granite, L.P. | Major Shareholder | Buy | 66,474 | $14.00 | $930,636.00 | | |
(Data available from 1/1/2013 forward)
Enanta Pharmaceuticals (NASDAQ ENTA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Enanta Pharmaceuticals (ENTA) VP Nathalie Adda Sells 4,225 Shares
www.americanbankingnews.com - April 18 at 7:29 PM |
 | Blog Exposure - Enanta Pharma Announced Presentation of New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH
finance.yahoo.com - April 16 at 8:55 AM |
| $30.01 Million in Sales Expected for Enanta Pharmaceuticals (ENTA) This Quarter
www.americanbankingnews.com - April 13 at 2:21 AM |
| Robert W. Baird Boosts Enanta Pharmaceuticals (ENTA) Price Target to $36.00
www.americanbankingnews.com - April 12 at 8:29 PM |
| Enanta Pharmaceuticals (ENTA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 12 at 11:47 AM |
| Enanta Pharmaceuticals (ENTA) Expected to Post Earnings of $0.10 Per Share
www.americanbankingnews.com - April 11 at 5:18 PM |
| Enanta Pharmaceuticals (ENTA) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 10 at 11:04 PM |
| Rigel Pharmaceuticals (RIGL) Soars: Stock Adds 8.2% in Session
finance.yahoo.com - April 5 at 11:05 AM |
| Bio-Path Leukemia Combo Study Shows Positive Early Data
finance.yahoo.com - April 4 at 3:39 PM |
| Enanta Pharmaceuticals (ENTA) Rating Reiterated by Royal Bank of Canada
www.americanbankingnews.com - April 4 at 11:42 AM |
| Report: Developing Opportunities within Enanta Pharmaceuticals, ServisFirst Bancshares, Lion Biotechnologies, Peapack-Gladstone Financial, Analogic, and Akcea Therapeutics — Future Expectations, Projections Moving into 2018
finance.yahoo.com - April 4 at 9:05 AM |
| Enanta Pharmaceuticals (ENTA) Upgraded to Strong-Buy at ValuEngine
www.americanbankingnews.com - April 3 at 4:16 PM |
| Enanta Pharmaceuticals (ENTA) Rating Lowered to Sector Perform at Royal Bank of Canada
www.americanbankingnews.com - March 31 at 12:49 PM |
 | Enanta Pharma (ENTA) Announces Data Presentations at The International Liver Congress
www.streetinsider.com - March 28 at 4:47 PM |
 | Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress 2018
www.finanznachrichten.de - March 28 at 9:14 AM |
| Enanta Pharmaceuticals Inc (ENTA) Expected to Announce Quarterly Sales of $30.01 Million
www.americanbankingnews.com - March 27 at 3:40 AM |
| Zacks: Analysts Anticipate Enanta Pharmaceuticals Inc (ENTA) Will Announce Earnings of $0.10 Per Share
www.americanbankingnews.com - March 25 at 7:12 PM |
| Enanta Pharmaceuticals Inc (ENTA) Treasurer Paul J. Mellett Sells 9,000 Shares
www.americanbankingnews.com - March 20 at 7:34 PM |
| Enanta Pharmaceuticals Inc (ENTA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 18 at 11:40 AM |
| Enanta Pharmaceuticals (ENTA) Raised to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 14 at 7:50 PM |
| Enanta Pharmaceuticals Inc (ENTA) Expected to Post Quarterly Sales of $30.01 Million
www.americanbankingnews.com - March 10 at 6:06 AM |
| Analysts Expect Enanta Pharmaceuticals Inc (ENTA) to Post $0.10 EPS
www.americanbankingnews.com - March 8 at 1:36 PM |
| Bristol-Myers' Opdivo gets FDA Nod for Every Four Week Dosing
finance.yahoo.com - March 8 at 9:13 AM |
 | Annual HC Wainwright NASH Investor Conference - Business Wire (press release)
www.businesswire.com - March 7 at 5:43 PM |
| Dermira's Acne Candidate Fails in Pivotal Trials, Shares Sink
finance.yahoo.com - March 6 at 5:08 PM |
| Enanta Pharmaceuticals Inc (ENTA) Holdings Reduced by Stonepine Capital Management LLC
www.americanbankingnews.com - March 6 at 9:58 AM |
| Enanta Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright NASH Investor Conference
finance.yahoo.com - March 6 at 8:54 AM |
| Enanta Pharmaceuticals (ENTA) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 4 at 7:16 PM |
 | Commit To Buy Enanta Pharmaceuticals At $55, Earn 6% Annualized Using Options - Nasdaq
www.nasdaq.com - February 25 at 9:19 AM |
| Enanta Pharmaceuticals Inc (ENTA) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - February 21 at 11:42 AM |
 | AbbVie Presents New Data on Upadacitinib for Crohn's Disease
www.msn.com - February 21 at 9:01 AM |
| Analysts Anticipate Enanta Pharmaceuticals Inc (ENTA) Will Announce Quarterly Sales of $30.01 Million
www.americanbankingnews.com - February 21 at 2:58 AM |
| Enanta Pharmaceuticals Inc (ENTA) Expected to Post Earnings of $0.10 Per Share
www.americanbankingnews.com - February 19 at 7:20 PM |
| Enanta Pharmaceuticals (ENTA) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - February 12 at 11:18 PM |
| Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
finance.yahoo.com - February 12 at 9:26 AM |
| Enanta Pharmaceuticals (ENTA) Rating Lowered to Neutral at JPMorgan Chase & Co.
www.americanbankingnews.com - February 11 at 2:12 PM |
| Enanta Pharmaceuticals (ENTA) PT Raised to $78.00 at Royal Bank of Canada
www.americanbankingnews.com - February 11 at 1:06 PM |
| Enanta Pharmaceuticals (ENTA) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - February 10 at 11:40 AM |
| Should You Sell Enanta Pharmaceuticals Inc (NASDAQ:ENTA) At This PE Ratio?
finance.yahoo.com - February 8 at 4:07 PM |
| Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2017
finance.yahoo.com - February 8 at 8:38 AM |
| Enanta Pharmaceuticals posts 1Q profit
finance.yahoo.com - February 8 at 8:38 AM |
| Brokerages Expect Enanta Pharmaceuticals Inc (ENTA) to Announce $0.05 EPS
www.americanbankingnews.com - February 2 at 7:10 PM |
| Enanta Pharmaceuticals (ENTA) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 30 at 10:48 PM |
| Enanta Pharmaceuticals (ENTA) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - January 30 at 4:08 AM |
| Enanta Pharmaceuticals Inc (ENTA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 27 at 11:56 AM |
| Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2017
finance.yahoo.com - January 24 at 9:58 AM |
| Enanta Pharmaceuticals Inc (ENTA) Expected to Announce Quarterly Sales of $27.26 Million
www.americanbankingnews.com - January 18 at 2:38 AM |
| Enanta Pharmaceuticals Inc (ENTA) Expected to Announce Earnings of $0.05 Per Share
www.americanbankingnews.com - January 16 at 9:24 PM |
| Enanta Pharma (ENTA) Provides Updates on R&D Programs and Business Outlook Ahead of JP Morgan Healthcare ... - StreetInsider.com
www.streetinsider.com - January 7 at 5:32 PM |
| Enanta Pharma (ENTA) Provides Updates on R&D Programs and Business Outlook Ahead of J.P. Morgan Healthcare Conference
www.streetinsider.com - January 6 at 9:39 AM |
Enanta Pharmaceuticals (NASDAQ:ENTA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Enanta Pharmaceuticals (NASDAQ:ENTA) Income Statement, Balance Sheet and Cash Flow Statement
Enanta Pharmaceuticals (NASDAQ ENTA) Stock Chart for Thursday, April, 19, 2018
Loading chart…
